Neoadjuvant chemotherapy based on dose-dense epirubicin (E) plus cyclophosphamide (C) followed by docetaxel (D) plus trastuzumab (T), DT plus carboplatin (CBDCA), or DT plus HER2 double blockade in HER2-positive breast cancer patients. | Publicación